- Kalbitor
- Ruconest
- Icatibant
- Firazyre
- Berinert
- Orladeyo
- Cinryze
- Haegarda
- Takhzyro
- Others
Hereditary Angioedema Market was valued at USD 1,056.1 million in 2019 and grown at 37.4% CAGR over the historic years (2019-2022) to reach USD 2,737.3 Million in 2022. Hereditary Angioedema (HAE) is a hereditary disease. There is a 50% probability that a parent with HAE will pass it on to their offspring. As a result of a spontaneous gene mutation, HAE can also develop in people with no family history. HAE is managed by acute attack management, short-term prophylaxis, and long-term prophylaxis. The Kalbitor, Ruconest, Icatibant, Firazyr and Berinert are using for acute attack management. The Orladeyo, Cinryze, Haegarda, and Takhzyro drugs are using for short-term and long term prophylaxis treatment. The diversity of HAE's phenotype makes diagnosis challenging. Initial misdiagnoses happen frequently. For instance, HAE-related edoema can be mistaken for an allergic reaction. It is possible to misinterpret gastrointestinal symptoms for the gastrointestinal disease alone. Due to its rarity and significant symptom overlap with other conditions, HAE is rarely detected early, usually disregarded, and misdiagnosed. The right diagnosis typically takes a patient more than 10 years after the onset of symptoms. Even though the illness is uncommon, it is dangerous.
STAR 0125 for Hereditary Angioedema Therapeutics and Market Value (USD Million), 2027 -2030 in USA
KalVista (Sebetralstat – On Demand & KVD-824 - Prophylaxis) for Hereditary Angioedema Therapeutics and Market Value (USD Million), 2024 -2029 in USA
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Around 14 drug molecules are in various clinical developmental stages, the majority of the molecules are in phase-I & II clinical stages. And few drug molecules such as KVD-900, CSL 312; Factor XIIa antagonist monoclonal antibody, Donidalorsen, are in Phase III clinical developmental stages.
The hereditary angioedema market size was valued at USD 2,737.3 Million in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The hereditary angioedema market key players are CSL Behring (Garadacimab) Takeda Pharming Biocryst Pharmaceutics (BCX-4161) Pharvaris (PHA 121) Ionis Pharmaceuticals (Donidalorsen)
1.Executive Summary |
2.Global Hereditary Angioedema Market Introduction |
2.1.Global Hereditary Angioedema Market - Taxonomy |
2.2.Global Hereditary Angioedema Market - Definitions |
2.2.1. By Product Type |
2.2.2. By Drug Class |
2.2.3. By Route of Administration |
2.2.4. By Region |
3.Global Hereditary Angioedema Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Hereditary Angioedema Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Hereditary Angioedema Market By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Kalbitor |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Ruconest |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Icatibant |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Firazyre |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Berinert |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Orladeyo |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Cinryze |
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Haegarda |
5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.9. Takhzyro |
5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
5.10. Others |
5.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.10.3. Market Opportunity Analysis |
6.Global Hereditary Angioedema Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. C1-esterase inhibitor |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Bradykinin B2 receptor antagonist |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Kallikrein inhibitor |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Hereditary Angioedema Market By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Intravenous |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Subcutaneous |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Oral |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Hereditary Angioedema Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Hereditary Angioedema Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Kalbitor |
9.1.2.Ruconest |
9.1.3.Icatibant |
9.1.4.Firazyre |
9.1.5.Berinert |
9.1.6.Orladeyo |
9.1.7.Cinryze |
9.1.8.Haegarda |
9.1.9.Takhzyro |
9.1.10.Others |
9.2. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.C1-esterase inhibitor |
9.2.2.Bradykinin B2 receptor antagonist |
9.2.3.Kallikrein inhibitor |
9.2.4.Others |
9.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Intravenous |
9.3.2.Subcutaneous |
9.3.3.Oral |
9.3.4.Others |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Hereditary Angioedema Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Kalbitor |
10.1.2.Ruconest |
10.1.3.Icatibant |
10.1.4.Firazyre |
10.1.5.Berinert |
10.1.6.Orladeyo |
10.1.7.Cinryze |
10.1.8.Haegarda |
10.1.9.Takhzyro |
10.1.10.Others |
10.2. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.C1-esterase inhibitor |
10.2.2.Bradykinin B2 receptor antagonist |
10.2.3.Kallikrein inhibitor |
10.2.4.Others |
10.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Intravenous |
10.3.2.Subcutaneous |
10.3.3.Oral |
10.3.4.Others |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Hereditary Angioedema Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Kalbitor |
11.1.2.Ruconest |
11.1.3.Icatibant |
11.1.4.Firazyre |
11.1.5.Berinert |
11.1.6.Orladeyo |
11.1.7.Cinryze |
11.1.8.Haegarda |
11.1.9.Takhzyro |
11.1.10.Others |
11.2. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.C1-esterase inhibitor |
11.2.2.Bradykinin B2 receptor antagonist |
11.2.3.Kallikrein inhibitor |
11.2.4.Others |
11.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Intravenous |
11.3.2.Subcutaneous |
11.3.3.Oral |
11.3.4.Others |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Hereditary Angioedema Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Kalbitor |
12.1.2.Ruconest |
12.1.3.Icatibant |
12.1.4.Firazyre |
12.1.5.Berinert |
12.1.6.Orladeyo |
12.1.7.Cinryze |
12.1.8.Haegarda |
12.1.9.Takhzyro |
12.1.10.Others |
12.2. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.C1-esterase inhibitor |
12.2.2.Bradykinin B2 receptor antagonist |
12.2.3.Kallikrein inhibitor |
12.2.4.Others |
12.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Intravenous |
12.3.2.Subcutaneous |
12.3.3.Oral |
12.3.4.Others |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Hereditary Angioedema Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Kalbitor |
13.1.2.Ruconest |
13.1.3.Icatibant |
13.1.4.Firazyre |
13.1.5.Berinert |
13.1.6.Orladeyo |
13.1.7.Cinryze |
13.1.8.Haegarda |
13.1.9.Takhzyro |
13.1.10.Others |
13.2. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.C1-esterase inhibitor |
13.2.2.Bradykinin B2 receptor antagonist |
13.2.3.Kallikrein inhibitor |
13.2.4.Others |
13.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Intravenous |
13.3.2.Subcutaneous |
13.3.3.Oral |
13.3.4.Others |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.CSL Behring (Garadacimab) |
14.2.2.Takeda |
14.2.3.Pharming |
14.2.4.Biocryst Pharmaceutics (BCX-4161) |
14.2.5.Pharvaris (PHA 121) |
14.2.6.Ionis Pharmaceuticals (Donidalorsen) |
14.2.7.Attune Pharmaceuticals (ATN-249) |
14.2.8.Arrowhead Pharmaceuticals (ARO-F12) |
14.2.9.Adverum Biotechnologies |
14.2.10.KalVista Pharmaceuticals (KVD-900, KVD 824 & Factor XIIa inhibitors) |
14.2.11.Centogene |
14.2.12.Spark Therapeutics (Gene Therapy) |
15. Research Methodology |
16. Appendix and Abbreviations |